Khiron Life Sciences Corp.
KHRNH.V
TSX
| 09/30/2022 | 06/30/2022 | 03/31/2022 | 12/31/2021 | 09/30/2021 | |
|---|---|---|---|---|---|
| Net Income | -90.26% | -59.53% | -71.65% | -47.58% | 42.94% |
| Total Depreciation and Amortization | 28.35% | 37.64% | 25.69% | 1.47% | 71.65% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 521.06% | 898.31% | 1,113.26% | 9,452.37% | -181.28% |
| Change in Net Operating Assets | 85.45% | 144.51% | 157.25% | -22.53% | -12.00% |
| Cash from Operations | 28.89% | 28.09% | 31.53% | 11.65% | 18.93% |
| Capital Expenditure | -92.73% | -43.32% | -44.49% | 31.18% | 65.85% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -526.70% | -66,500.00% | -99.99% | -100.00% | -100.10% |
| Cash from Investing | -126.68% | -73.30% | -172.56% | -109.03% | -105.44% |
| Total Debt Issued | 275.44% | -- | -- | -- | -- |
| Total Debt Repaid | 126.33% | 114.84% | 70.93% | 80.72% | -60.95% |
| Issuance of Common Stock | -81.36% | 37.14% | -0.12% | -0.12% | -- |
| Repurchase of Common Stock | -- | -- | -- | -2,470.06% | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 600.03% | 450.22% | 578.50% | 578.50% | -135.08% |
| Cash from Financing | -79.26% | 31.06% | -10.17% | -9.22% | 3,050.68% |
| Foreign Exchange rate Adjustments | 84.88% | -566.69% | -8,302.04% | -495.90% | -47.06% |
| Miscellaneous Cash Flow Adjustments | -99.89% | 1,110.83% | 1,104.17% | 1,104.17% | 227.70% |
| Net Change in Cash | -3,268.07% | 67.32% | -8.70% | -209.17% | 115.67% |
